{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:57:23Z","timestamp":1789984643546,"version":"4.0.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroent\u00e9rologie Clinique et Biologique"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.gcb.2007.11.002","type":"journal-article","created":{"date-parts":[[2008,3,6]],"date-time":"2008-03-06T18:49:50Z","timestamp":1204829390000},"page":"134-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Foie et m\u00e9thotrexate"],"prefix":"10.1016","volume":"32","author":[{"given":"D.","family":"Laharie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Terrebonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vergniol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Chanteloup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Chabrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Couzigou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"de L\u00e9dinghen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gcb.2007.11.002_bib1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0002-9343(85)90312-2","article-title":"Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations","volume":"79","author":"Weinstein","year":"1985","journal-title":"Am J Med"},{"key":"10.1016\/j.gcb.2007.11.002_bib2","first-page":"823","article-title":"Methotrexate induced hepatitis in childhood leukemia","volume":"1","author":"Taft","year":"1965","journal-title":"Isr J Med Sci"},{"key":"10.1016\/j.gcb.2007.11.002_bib3","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/ard.2003.016337","article-title":"Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene","volume":"63","author":"Berkun","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gcb.2007.11.002_bib4","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","article-title":"Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study","volume":"44","author":"van Ede","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gcb.2007.11.002_bib5","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1046\/j.1440-1746.2001.02644.x","article-title":"Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury","volume":"16","author":"Langman","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib6","first-page":"511","article-title":"Liver biopsies from psoriatics related to methotrexate therapy. Findings in post-methotrexate liver biopsies from 160 psoriatics","volume":"85","author":"Nyfors","year":"1977","journal-title":"Acta Pathol Microbiol Scand [A]"},{"key":"10.1016\/j.gcb.2007.11.002_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0190-9622(88)80237-8","article-title":"Methotrexate in psoriasis: revised guidelines","volume":"19","author":"Roenigk","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2165\/00128071-200506060-00003","article-title":"Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary?","volume":"6","author":"Thomas","year":"2005","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.clpt.2003.12.001","article-title":"Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity","volume":"75","author":"Nygaard","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.gcb.2007.11.002_bib10","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1200\/JCO.1997.15.4.1560","article-title":"Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia","volume":"15","author":"Farrow","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gcb.2007.11.002_bib11","first-page":"1730","article-title":"Methotrexate in Crohn's disease: long-term efficacy and toxicity","volume":"95","author":"Lemann","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gcb.2007.11.002_bib12","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1111\/j.1572-0241.2000.03287.x","article-title":"Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease","volume":"95","author":"Te","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gcb.2007.11.002_bib13","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/j.1365-2036.2006.02929.x","article-title":"Diagnosis of liver fibrosis by transient elastography (FibroScan) and noninvasive methods in Crohn's disease patients treated with methotrexate","volume":"23","author":"Laharie","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gcb.2007.11.002_bib14","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/art.1780290702","article-title":"The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis","volume":"29","author":"Kremer","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gcb.2007.11.002_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1365-2133.1994.tb02901.x","article-title":"Methotrexate revisited: effects of long-term treatment in psoriasis","volume":"130","author":"Van Dooren-Greebe","year":"1994","journal-title":"Br J Dermatol"},{"issue":"Suppl 12","key":"10.1016\/j.gcb.2007.11.002_bib16","first-page":"29","article-title":"Methotrexate and the liver","volume":"12","author":"Tolman","year":"1985","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.gcb.2007.11.002_bib17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archinte.1973.03650090071013","article-title":"Hepatotoxicity of long-term methotrexate therapy for psoriasis","volume":"132","author":"Tobias","year":"1973","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.gcb.2007.11.002_bib18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3949\/ccjm.54.4.327","article-title":"Methotrexate in the treatment of arthritis and connective tissue diseases","volume":"54","author":"Wilke","year":"1987","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.gcb.2007.11.002_bib19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2133.1980.tb06553.x","article-title":"Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment","volume":"102","author":"Zachariae","year":"1980","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/archderm.1969.01610290007002","article-title":"Cirrhosis caused by methotrexate in the treatment of psoriasis","volume":"100","author":"Muller","year":"1969","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib21","first-page":"262","article-title":"Liver biopsies from psoriatics related to methotrexate therapy. Findings before and after methotexate therapy in 88 patients. A blind study","volume":"84","author":"Nyfors","year":"1976","journal-title":"Acta Pathol Microbiol Scand [A]"},{"key":"10.1016\/j.gcb.2007.11.002_bib22","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2007.01.024","article-title":"Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment","volume":"46","author":"Rosenberg","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1001\/archderm.1970.04000110014002","article-title":"Liver disease associated with methotrexate treatment of psoriatic patients","volume":"102","author":"Dubin","year":"1970","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1001\/archderm.1969.01610290015003","article-title":"Cirrhosis following methotrexate administration for psoriasis","volume":"100","author":"Epstein","year":"1969","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.62.5.423","article-title":"Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis","volume":"62","author":"Hoekstra","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gcb.2007.11.002_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/rheumatology\/keh088","article-title":"Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review","volume":"43","author":"Whittle","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.gcb.2007.11.002_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/art.1780330102","article-title":"The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis","volume":"33","author":"Morgan","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gcb.2007.11.002_bib28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/archinte.1964.00280080027006","article-title":"Methotrexate-induced hepatic injury in an adult. A case report","volume":"113","author":"O\u2019Rourke","year":"1964","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.gcb.2007.11.002_bib29","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0002-9343(05)80060-9","article-title":"Methotrexate and histologic hepatic abnormalities: a meta-analysis","volume":"90","author":"Whiting-O\u2019Keefe","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.gcb.2007.11.002_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.1990.tb08232.x","article-title":"Serum type III procollagen peptide, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate","volume":"122","author":"Mitchell","year":"1990","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib31","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1365-2133.1995.tb02754.x","article-title":"Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal","volume":"133","author":"Boffa","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib32","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0190-9622(03)00803-X","article-title":"Methotrexate and psoriasis in the era of new biologic agents","volume":"50","author":"Saporito","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00004836-199312000-00010","article-title":"Fulminant hepatic failure after methotrexate and PUVA therapy for psoriasis","volume":"17","author":"Markin","year":"1993","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gcb.2007.11.002_bib34","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0002-9343(88)80019-6","article-title":"Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis","volume":"85","author":"Shergy","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.gcb.2007.11.002_bib35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/archderm.1980.01640280049016","article-title":"Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals","volume":"116","author":"Robinson","year":"1980","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib36","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/BF01308193","article-title":"Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. An acceptable risk\/benefit ratio","volume":"30","author":"Lanse","year":"1985","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gcb.2007.11.002_bib37","first-page":"2092","article-title":"Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis","volume":"29","author":"Fathi","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib38","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/00007611-198605000-00005","article-title":"Hepatotoxicity after long-term methotrexate therapy","volume":"79","author":"Reynolds","year":"1986","journal-title":"South Med J"},{"key":"10.1016\/j.gcb.2007.11.002_bib39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2133.2005.06605.x","article-title":"Noninvasive monitoring for methotrexate hepatotoxicity","volume":"152","author":"MacDonald","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib40","first-page":"229","article-title":"Clinical liver disease in patients with rheumatoid arthritis taking methotrexate","volume":"19","author":"Phillips","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib41","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/archderm.1989.01670210056007","article-title":"The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment","volume":"125","author":"Newman","year":"1989","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib42","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0190-9622(98)70508-0","article-title":"Methotrexate in psoriasis: consensus conference","volume":"38","author":"Roenigk","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib43","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2036.2004.01819.x","article-title":"Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?","volume":"19","author":"Aithal","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gcb.2007.11.002_bib44","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1478-3231.2007.01489.x","article-title":"Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and FibroScan predicts the absence of significant liver fibrosis","volume":"27","author":"Berends","year":"2007","journal-title":"Liver Int"},{"key":"10.1016\/j.gcb.2007.11.002_bib45","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.1780370304","article-title":"Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology","volume":"37","author":"Kremer","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gcb.2007.11.002_bib46","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jbspin.2006.01.007","article-title":"Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion","volume":"73","author":"Pavy","year":"2006","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.gcb.2007.11.002_bib47","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/bmj.1.5801.654","article-title":"Methotrexate hepatotoxicity in psoriasis: comparison of different dose regimens","volume":"1","author":"Dahl","year":"1972","journal-title":"Br Med J"},{"key":"10.1016\/j.gcb.2007.11.002_bib48","first-page":"787","article-title":"Liver injury associated with methotrexate therapy for psoriasis","volume":"48","author":"Podurgiel","year":"1973","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.gcb.2007.11.002_bib49","first-page":"369","article-title":"Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up","volume":"10","author":"Malatjalian","year":"1996","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.gcb.2007.11.002_bib50","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2133.1975.tb06498.x","article-title":"A prospective study of the effects of weekly oral methotrexate on liver biopsy","volume":"93","author":"Warin","year":"1975","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib51","doi-asserted-by":"crossref","first-page":"358","DOI":"10.7326\/0003-4819-107-2-358","article-title":"Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety","volume":"107","author":"Tugwell","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gcb.2007.11.002_bib52","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3949\/ccjm.52.2.129","article-title":"Hepatotoxicity of prolonged methotrexate therapy for rheumatoid arthritis","volume":"52","author":"Mackenzie","year":"1985","journal-title":"Cleve Clin Q"},{"key":"10.1016\/j.gcb.2007.11.002_bib53","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/art.20167","article-title":"Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial","volume":"50","author":"Lambert","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gcb.2007.11.002_bib54","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00044011-200626020-00001","article-title":"Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis","volume":"26","author":"Tilling","year":"2006","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.gcb.2007.11.002_bib55","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00393-003-0458-2","article-title":"Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases","volume":"62","author":"Ujfalussy","year":"2003","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib56","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/art.1780311201","article-title":"Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate","volume":"31","author":"Aponte","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gcb.2007.11.002_bib57","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/1523-1747.ep12679887","article-title":"Effects of methotrexate on the liver in psoriasis","volume":"62","author":"Reese","year":"1974","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib58","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0889-857X(05)70365-3","article-title":"Methotrexate hepatotoxicity","volume":"23","author":"West","year":"1997","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.gcb.2007.11.002_bib59","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2133.1985.tb02405.x","article-title":"Ultrasound as a screening procedure for methotrexate-induced hepatic damage in severe psoriasis","volume":"113","author":"Miller","year":"1985","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib60","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2133.1987.tb05867.x","article-title":"A comparison of liver ultrasound with liver biopsy histology in psoriatics receiving long-term methotrexate therapy","volume":"116","author":"Coulson","year":"1987","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib61","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0190-9622(82)80064-9","article-title":"Methotrexate guidelines: revised","volume":"6","author":"Roenigk","year":"1982","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.gcb.2007.11.002_bib62","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1136\/gut.2005.081950b","article-title":"European evidence based consensus on the diagnosis and management of Crohn's disease: current management","volume":"55","author":"Travis","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.gcb.2007.11.002_bib63","first-page":"1337","article-title":"Methotrexate-induced chronic liver injury: guidelines for detection and prevention. The ACG Committee on FDA-related matters. American College of Gastroenterology","volume":"83","author":"Lewis","year":"1988","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gcb.2007.11.002_bib64","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1155\/2005\/382379","article-title":"A survey of Canadian gastroenterologists about the use of methotrexate in patients with Crohn's disease","volume":"19","author":"Chande","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.gcb.2007.11.002_bib65","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0190-9622(00)90237-8","article-title":"Liver biopsies and methotrexate: a time for reconsideration?","volume":"42","author":"Zachariae","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib66","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2340\/0001555572361364","article-title":"Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy","volume":"72","author":"Themido","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.gcb.2007.11.002_bib67","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/00124743-200108000-00007","article-title":"Liver biopsy in psoriatic arthritis to detect methotrexate hepatotoxicity","volume":"7","author":"Grismer","year":"2001","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.gcb.2007.11.002_bib68","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/archderm.1971.04000150020003","article-title":"Hepatotoxicity of methotrexate in the treatment of psoriasis","volume":"103","author":"Roenigk","year":"1971","journal-title":"Arch Dermatol"}],"container-title":["Gastroent\u00e9rologie Clinique et Biologique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399832008000286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399832008000286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:45:10Z","timestamp":1759974310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399832008000286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0399832008000286"],"URL":"https:\/\/doi.org\/10.1016\/j.gcb.2007.11.002","relation":{},"ISSN":["0399-8320"],"issn-type":[{"value":"0399-8320","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Foie et m\u00e9thotrexate","name":"articletitle","label":"Article Title"},{"value":"Gastroent\u00e9rologie Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gcb.2007.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}